TY - JOUR
T1 - Thyroid carcinoma, version 2.2018 featured updates to the NCCN guidelines
AU - Haddad, Robert I.
AU - Nasr, Christian
AU - Bischoff, Lindsay
AU - Busaidy, Naifa Lamki
AU - Byrd, David
AU - Callender, Glenda
AU - Dickson, Paxton
AU - Duh, Quan Yang
AU - Ehya, Hormoz
AU - Goldner, Whitney
AU - Haymart, Megan
AU - Hoh, Carl
AU - Hunt, Jason P.
AU - Iagaru, Andrei
AU - Kandeel, Fouad
AU - Kopp, Peter
AU - Lamonica, Dominick M.
AU - McIver, Bryan
AU - Raeburn, Christopher D.
AU - Ridge, John A.
AU - Ringel, Matthew D.
AU - Scheri, Randall P.
AU - Shah, Jatin P.
AU - Sippel, Rebecca
AU - Smallridge, Robert C.
AU - Sturgeon, Cord
AU - Wang, Thomas N.
AU - Wirth, Lori J.
AU - Wong, Richard J.
AU - Johnson-Chilla, Alyse
AU - Hoffmann, Karin G.
AU - Gurski, Lisa A.
N1 - Funding Information:
This activity is supported by educational grants from AstraZeneca, Celldex Therapeutics, Celgene Corporation, Genentech, Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Seattle Genetics, Inc. This activity is supported by independent educational grants from AbbVie, Merck & Co., Inc. and NOVOCURE.
Publisher Copyright:
© National Comprehensive Cancer Network, Inc. 2018, All rights reserved.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
AB - The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hürthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E–mutated anaplastic thyroid carcinoma.
UR - http://www.scopus.com/inward/record.url?scp=85058746008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058746008&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2018.0089
DO - 10.6004/jnccn.2018.0089
M3 - Article
C2 - 30545990
AN - SCOPUS:85058746008
SN - 1540-1405
VL - 16
SP - 1429
EP - 1440
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 12
ER -